Cepheid announced an updated third-generation GeneXpert infectious disease PCR platform aimed at faster workflows and higher-plex panels while maintaining compatibility with the current test menu. The company plans shipments of a compact four-module configuration to U.S. customers and is developing additional higher-capacity systems. Separately, Science Corp. launched its Prima retinal implant in Europe after receiving CE mark approval under the Medical Device Regulation, marking a step toward commercialization for brain-computer interface technology that writes visual information into the nervous system. Together, the updates show continued momentum in both lab-based infectious diagnostics and device-led neurotechnology—two tracks with different regulatory pathways but shared pressure for performance evidence and scalable deployment.